
iRhythm Stock Jumps on Strong Q4 Results and FDA Progress
Sales beat expectations; regulatory remediation on track iRhythm (Nasdaq: IRTC) shares surged 8% following better-than-expected Q4 results and progress in addressing FDA compliance concerns. Key